Generation of Plasmodium berghei malaria models to test vaccine formulations against Plasmodium vivax.
Background: Malaria is a preventable, diagnosable and treatable disease. Yet, the disease causes thousands of deaths every year, and millions of people are still endangered. Almost all malaria cases worldwide are due to infection with Plasmodium vivax or P. falciparum. There is an urgent need to eliminate malaria, since drug resistance is reappearing, and there seems to be a general agreement that elimination is not simply a matter of intensifying the use of available tools. New strategies, like efficient vaccines, will be required. Developing a malaria vaccine is one of the greatest challenges in biomedical sciences. Vaccine development against P. vivax is even more challenging, because the parasite cannot be continuously cultured in laboratories. The lack of cultures has been an obstacle slowing pre-clinical tests of vaccine formulations against P. vivax based on known antigens. The aim of this project is to move forward with P. vivax vaccine development by generating a platform to test available formulations. Materials and Methods: Two chimeric P. berghei lines(ANKA and NK65) were modified to express PvMSP1-19 instead of the endogenous PbMSP1-19. These parasites are used to challenge C57BL/6 or BALB/c mice previously immunized with vaccine formulations based on the PvMSP1-19. Mice were then challenged two weeks after last dose and parasitemia was monitored every day.Results: The mutant lines were generated and have no impact in asexual growth in vivo, showing that the PvMSP1-19 can correctly complement the function of the endogenous PbMSP1-19. Both lines expressed PvMSP1-19 correctly, as confirmed by anti-PvMSP1-19 MAb staining and by western blot. After immunization and challenge, a high and specific anti-PvMSP1-19 was not sufficient to protect mice against infection with the chimeric ANKA line. Experiments using the NK65 chimeric line are in course.Conclusions: Here we show that replacement of PbMSP1-19 by the P. vivax homolog sequence is possible, and mutant parasites obtained infect hosts similarly to the WT P. berghei strains. Our results indicate that the P. berghei ANKA somehow circumvents the anti-MSP1-19 response, as suggested by previous reports. Whether this also happens with the NK65 line, which reflects more closely a P. vivax infection, is under investigation.